NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Accelovance (China) Co., Ltd. back to previous page show list

Accelovance (China) Co., Ltd.

address: Accelovance (China) Co., Ltd.
Yuanyang International Building, Tower D
Suite 2304

No. 26 East 4th Ring Middle Road
Changyang District
Beijing 100025, PR China
contact: (p) 86.10.8528.8906
(f) 86.10.8528.8907

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 
Accelovance,Inc.,based in Rockville, Maryland, is a Clinical Research Organization (CRO) that owns Clinical Sites and a Patient Recruitment department with call center. They increase productivity on trials by utilizing  high throughput system. Through this integration and  patient pooling processes, Accelovance brings an unprecedented level of control to trials. The result is high quality trials completed in compressed timelines and cost effectively.
 
Each study is approached with the intent to complete enrollment before the study starts. With critical planning and full control of patient recruitment and clinical facility operations, Accelovance is committed to delivering high quality, predictable, and cost effective clinical trials.
 
Accelovance (China) Corp Ltd.,
Accelovance (China) Corp Ltd.a wholly foreign owned enterprise of Accelovance, Inc., is a clinical CRO and market commercialization services company with offices in Beijing and Shanghai, P.R. China. Accelovance (China) fully leverages its relationship with its parent company, to deliver high quality clinical services in compliance with international standards. In addition, Accelovance (China) works with sponsors to realize the value of the China pharmaceutical market, which is the fastest growing in the world.
 
Definig & Capitalizing on the Opportunity
 
China Clinical Services
 
Understanding the China market opportunities and challenges allows Accelovance to optimize value for sponsors relative to the following needs:
 
  • Troubled Study Due to Recruitment
  • Planned Study in Difficult to Recruit Indications (Oncology, Hepatitis, Infectious Disease, etc.)
  • Seeking New Markets
  • Seeking Economic Value
  • Proof-of-Concept Clinical Studies (Phase I Completed in West)
  • Fulfill Demographic Requirement  

    Services

    Accelovance (China) operates to deliver ICH-GCP compliant clinical trials. Its staff has strong experience in conducting ICH-GCP clinical trials for multinational client and it utilizes the same clinical SOPs as U.S. based Accelovance, Inc.. Depending on your needs, Accelovance (China) offers the following services: 

  • Regulatory  
  • Project Management
  • Monitoring
  • Quality Control/Study Coordination
  • Data Management/Biostatistics
  • Market Commercialization  

    Value

    Based on a thorough understanding of your needs, Accelovance is committed to deliver high quality services to help you realize your goals. We look to build long-term relationships and be viewed as a valued partner in your success. 

  • High Quality & Cost Effective Studies 
  • Revenue with Market Entry  
     
    Market Registration Services
     
    With a presence in both the United States and China, Accelovance can facilitate the establishment of relationships necessary to optimize a products' revenue potential in the China market. Emphasizing value to its pharmaceutical partners, Accelovance is flexible in the way it structures relationships/partnerships. These structures may include the development of Joint Ventures, Licensing, and/or Broker/Agent. This approach affords partners the opportunity to increase their revenues with as little or as much involvement as they require or have resources to commit.
    Accelovance will use its expertise, industry knowledge and its high level government and industry relationships to comprehensively move a product through the following key areas into China’s pharmaceutical marketplace.

    • Market Research
      • Legal (IP, Trademark, etc.)
      • Partner Evaluation/Selection
      • Relationship Structure (JV, Licensing)
      • Develop JV/Partnership Management Structure
    • Business Formation
    • Import Drug Registration
    • Manufacturing/Packaging
    • Marketing & Sales
    • Distribution
    Drug development companies can take advantage of the tremendous opportunity in China to increase revenues by entering the world’s fastest growing market. At $7 billion, China is currently the seventh largest pharmaceutical market globally; however, projections from Boston Consulting Group data indicate it will be fifth by 2010 at $24 billion, and some believe in the top three by 2020 at an estimated $120 billion. 

     


  • AngloChinese Investments ltd.
    Home | Company news | TOP 50 | Events | About us
    C&F Bright Solutions ltd.